



BIOIMPACT EXTENDS LICENSE AGREEMENT WITH RLS GLOBAL

BTC health (as the trading name of Biotech Capital Limited) (ASX:BTC) announced today that its wholly owned subsidiary BioImpact Pty Ltd has extended its exclusive license and supply agreement with RLS Global AB of Sweden to include two additional products.

RLS Global has effective immediately, granted BioImpact the rights to distribute the novel dental products **Perisolv** and **Carisolv** within Australia, New Zealand and select countries across the Asia Pacific region.

Perisolv is a patented, biochemically active gel that optimizes the dental professionals treatment of periodontitis, mucositis and peri-implantitis. The gel is CE approved and when applied directly to the periodontal pocket it exerts a bacteriostatic effect and aids in dissolving degenerated tissue making the debridement easier for both dental professionals and patients.

<http://perisolv.com/en>

Carisolv is a patented gel that assists in the removal and treatment of dental caries. It is a minimally invasive treatment that gives better bonding strength to the filling.

<http://carisolvsystem.com/en>

Perisolv and **Carisolv** are classified as medical devices. Subject to inclusion on the Australian Register of Therapeutic Goods (ARTG), it is anticipated that both products will be made available in Australia during the current financial year.

BTC health Chairman Dr. Richard Treagus commented; "We are delighted to be extending our current partnering arrangements with RLS Global and we look forward to making Perisolv and Carisolv available to dental customers in Australia and more broadly across the Asia Pacific region."

About RLS Global AB

RLS Global is a Swedish medtech company based in Gothenburg. RLS Global develops and sells biochemical products and methods for treatment of some of the world's most common diseases. RLS Global has a portfolio of products including wound care product **Chlorasolv**® and dental products **Carisolv**® and **Perisolv**®. The company is dedicated to help in the fight against antibiotic resistance.

**About Peridontitis**

Periodontitis is an advanced gum disease that may occur if gingivitis is not treated. It is characterised by redness, swelling and bleeding of the gums. The part of the gum that seals to the tooth is weakened and spaces called “periodontal pockets” form between the tooth and the gum. Bacteria become trapped in these pockets causing further inflammation. Peri-implantitis is the equivalent to Periodontitis and occurs around dental implants. The disease is difficult to treat and may in some case progress quickly.

About Dental Caries

Dental caries is a breakdown of the hard tissues (enamel, dentin and cementum) of the teeth due to acids made by bacteria. The acid is produced from sugars on the tooth surface.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.

For more information, please contact:

Dr. Richard Treagus, Executive Chairman
rtreagus@btchealth.com.au

+61 417 520 509